Vitamin D in autoimmune rheumatic diseases: A view inside gender differences

Pharmacological Research

Volumn 117, Issue , 2017, Pages 228-241

  Vasile, Massimiliano ^a,b   Corinaldesi, Clarissa ^a,c   Antinozzi, Cristina ^a   Crescioli, Clara ^a  

^a UNIVERSITY OF ROME FORO ITALICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Autoimmunity; Gender; Rheumatic diseases; Sex hormones; Therapy; Vitamin D

Indexed keywords

ANDROGEN; ANTIRHEUMATIC AGENT; ESTROGEN; SEX HORMONE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR AGONIST; CALCITRIOL RECEPTOR;

AUTOIMMUNE DISEASE; AUTOIMMUNE RHEUMATIC DISEASE; AUTOIMMUNE RHEUMATIC DISEASES; DISEASE ASSOCIATION; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; MYOPATHY; MYOSITIS; NONHUMAN; PATHOGENESIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SEX DIFFERENCE; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION; ANIMAL; IMMUNOLOGY; METABOLISM; SEXUAL CHARACTERISTICS;

ANIMALS; AUTOIMMUNE DISEASES; GONADAL STEROID HORMONES; HUMANS; RECEPTORS, CALCITRIOL; RHEUMATIC DISEASES; SEX CHARACTERISTICS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 85008330592     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.12.038     Document Type: Review

References (261)

1. [1] Holick, M.F., Vitamin D deficiency. N. Engl. J. Med.(3), 2007, 266–281 (19;357).
2. [2] Wahl, D.A., Cooper, C., Ebeling, P.R., Eggersdorfer, M., Hilger, J., Hoffmann, K., Josse, R., Kanis, J.A., Mithal, A., Pierroz, D.D., Stenmark, J., Stöcklin, E., Dawson-Hughes, B., A global representation of vitamin D status in healthy populations. Arch. Osteoporos. 7:1–2 (2012), 155–172.
3. [3] Scrivo, R., Vasile, M., Bartosiewicz, I., Valesini, G., Inflammation as common soil of the multifactorial diseases. Autoimmun. Rev. 10:7 (2011), 369–374.
4. [4] Cantorna, M.T., Mahon, B.D., D-hormone and the immune system. J. Rheumatol. Suppl. 76 (2005), 11–20.
5. [5] Holick, M.F., Vitamin D: evolutionary, physiological and health perspectives. Curr. Drug Targets 12 (2011), 4–18.
6. [6] Arnson, Y., Amital, H., Agmon-Levin, N., Alon, D., Sánchez-Castañón, M., López-Hoyos, M., Matucci-Cerinic, M., Szücs, G., Shapira, Y., Szekanecz, Z., Shoenfeld, Y., Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun. Rev. 10 (2011), 490–494.
7. [7] Lehmann, B., Genehr, T., Knuschke, P., Pietzsch, J., Meurer, M., UVB-induced conversion of 7-dehydrocholesterol to 1a,25Dihydroxyvitamin D3 in an in vitro human skin equivalent model. J. Invest. Dermatol. 117:5 (2001), 1179–1185.
8. [8] Bouillon, R., Okamura, W.H., Norman, A.W., Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. 16 (1995), 200–257.
9. [9] Carlberg, C., Seuter, S., Heikkinen, S., The first genome-wide view of Vitamin D receptor locations and their mechanistic implications. Anticancer Res. 32 (2012), 271–282.
10. [10] Hossein-Nezhad, A., Spira, A., Holick, M.F., Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial. PLoS One, 8(3), 2013, e58725.
11. [11] Norman, A.W., Ishizuka, S., Okamura, W.H., Ligands for the vitamin D endocrine system: different shapes function as agonists and antagonists for genomic and rapid response receptors or as a ligand for the plasma vitamin D binding protein. J. Steroid Biochem. Mol. Biol. 76:1–5 (2001), 49–59.
12. [12] De Luca, H.F., Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr. 80:Suppl. 6 (2004), 1689S–1696S.
13. [13] Wolpowitz, D., Gilchrest, B.A., The vitamin D questions: how much do you need and how should you get it?. J. Am. Acad. Dermatol. 54 (2006), 301–317.
14. [14] Adams, J.S., Clemens, T.L., Parrish, J.A., Holick, M.F., Vitamin-D synthesis and metabolism after ultraviolet irradiation of normal and vitamin-D deficient subjects. N. Engl. J. Med. 306 (1982), 722–725.
15. [15] Reichel, H., Koeffler, H.P., Norman, A.W., The role of the vitamin D endocrine system in health and disease. N. Engl. J. Med. 320 (1989), 980–991.
16. [16] Bendik, I., Friedel, A., Roos, F.F., Weber, P., Eggersdorfer, M., Vitamin D: a critical and essential micronutrient for human health. Front. Physiol., 11(5), 2014, 248.
17. [17] Hagenau, T., Vest, R., Gissel, T.N., Poulsen, C.S., Erlandsen, M., Mosekilde, L., Vestergaard, P., Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos. Int. 20 (2009), 133–140.
18. [18] McCullough, M.L., Weinstein, S.J., Freedman, D.M., Helzlsouer, K., Flanders, W.D., Koenig, K., Kolonel, L., Laden, F., Le Marchand, L., Purdue, M., Snyder, K., Stevens, V.L., Stolzenberg-Solomon, R., Virtamo, J., Yang, G., Yu, K., Zheng, W., Albanes, D., Ashby, J., Bertrand, K., Cai, H., Chen, Y., Gallicchio, L., Giovannucci, E., Jacobs, E.J., Hankinson, S.E., Hartge, P., Hartmuller, V., Harvey, C., Hayes, R.B., Horst, R.L., Shu, X.O., Correlates of circulating 25-hydroxyvitamin D: cohort consortium Vitamin D pooling project of rarer cancers. Am. J. Epidemiol.(1), 2010, 21–35 (1,172).
19. [19] Holick, M.F., Matsuoka, L.Y., Wortsman, J., Age, vitaminD, and solar ultraviolet. Lancet 2 (1989), 1104–1105.
20. [20] MacLaughlin, J., Holick, M.F., Aging decreases the capacity of human skin to produce vitaminD3. J. Clin. Invest. 76 (1985), 1536–1538.
21. [21] Jungert, A., Neuhäuser-Berthold, M., Sex-specific determinants of serum 25-hydroxyvitamin D3 concentrations in an elderly German cohort: a cross-sectional study. Nutr. Metab., 12, 2015, 2.
22. [22] Holick, M.F., Chen, T.C., Vitamin D deficiency: a worldwide problem with health consequences. Am. J. Clin. Nutr. 87:4 (2008), 1080S–1086S.
23. [23] Ross, A.C., Manson, J.E., Abrams, S.A., Aloia, J.F., Brannon, P.M., Clinton, S.K., Durazo-Arvizu, R.A., Gallagher, J.C., Gallo, R.L., Jones, G., Kovacs, C.S., Mayne, S.T., Rosen, C.J., Shapses, S.A., The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 96 (2011), 53–58.
24. [24] Holick, M.F., Binkley, N.C., Bischoff-Ferrari, H.A., Gordon, C.M., Hanley, D.A., Heaney, R.P., Murad, M.H., Weaver, C.M., Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96 (2011), 1911–1930.
25. [25] Fletcher, J.M., Basdeo, S.A., Allen, A.C., Dunne, P.J., Therapeutic use of vitamin D and its analogues in autoimmunity. Recent Pat. Inflamm. Allergy Drug Discov. 6:1 (2012), 22–34.
26. [26] Rosen, C.J., Clinical practice. Vitamin D insufficiency. N. Engl. J. Med. 364:3 (2011), 248–254.
27. [27] Basile, L.A., Taylorm, S.N., Wagnerm, C.L., Quinonesm, L., Hollism, B.W., Neonatal vitamin D status at birth at latitude 32degrees 72': Evidence of deficiency. J. Perinatol. 27:9 (2007), 568–571.
28. [28] Wortsman, J., Matsuoka, L.Y., Chen, T.C., Lu, Z., Holick, M.F., Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr. 72:3 (2000), 690–693.
29. [29] Lagunova, Z., Porojnicm, C., Lindberg, F., Hexeberg, S., Moan, J., The dependency of Vitamin D status on body mass index, gender, age and season. Anticancer Res. 29:9 (2009), 3713–3720.
30. [30] Agmon-Levin, N., Kivity, S., Tzioufas, A.G., López Hoyos, M., Rozman, B., Efes, I., Shapira, Y., Shamis, A., Amital, H., Youinou, P., Shoenfeld, Y., Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjogren's syndrome. J. Autoimmun. 39 (2012), 234–239.
31. [31] Giovannucci, E., Vitamin D and cancer incidence in the Harvard cohorts. Ann. Epidemiol. 19:2 (2009), 84–88.
32. [32] Twig, G., Shina, A., Amital, H., Shoenfeld, Y., Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity. J. Autoimmun. 38:2–3 (2012), 275–281.
33. [33] Anderson, J.L., May, H.T., Horne, B.D., Bair, T.L., Hall, N.L., Carlquist, J.F., Lappé, D.L., Muhlestein, J.B., Intermountain Heart Collaborative (IHC) Study Group, Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am. J. Cardiol. 106:7 (2010), 963–968.
34. [34] Qazi, R.A., Martin, K.J., Vitamin D in kidney disease: pathophysiology and the utility of treatment. Rheum. Dis. Clin. N. Am. 38:1 (2012), 115–123.
35. [35] Pittas, A.G., Dawson-Hughes, B., Vitamin D and diabetes. J. Steroid Biochem. Mol. Biol. 121:1–2 (2010), 425–429.
36. [36] Deluca, H.F., Cantorna, M.T., Vitamin D: its role and uses in immunology. FASEB J. 15:14 (2001), 2579–2585.
37. [37] Adorini, L., Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell. Immunol. 233:2 (2005), 115–124.
38. [38] van Etten, E., Mathieu, C., Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J. Steroid Biochem. Mol. Biol. 97:1–2 (2005), 93–101.
39. [39] Adorini, L., Penna, G., Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 4:8 (2008), 404–412.
40. [40] Bikle, D.D., What is new in vitamin D: 2006–2007. Curr. Opin. Rheumatol. 19:4 (2007), 383–388.
41. [41] Hart, P.H., Gorman, S., Finlay-Jones, J.J., Modulation of the immune system by UV radiation: more than just the effects of vitamin D?. Nat. Rev. Immunol. 11:9 (2011), 584–596.
42. [42] Gregori, S., Casorati, M., Amuchastegui, S., Smiroldo, S., Davalli, A.M., Adorini, L., Regulatory T cells induced by 1α,25dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 167:4 (2001), 1945–1953.
43. [43] Penna, G., Roncari, A., Amuchastegui, S., Daniel, K.C., Berti, E., Colonna, M., Adorini, L., Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4 + Foxp3+ regulatory T cells by 1,25dihydroxyvitamin D3. Blood 106:10 (2005), 3490–3497.
44. [44] Dong, X., Bachman, L.A., Kumar, R., Griffin, M.D., Generation of antigen-specific interleukin-10-producing T-cells using dendritic cell stimulation and steroid hormone conditioning. Transpl. Immunol. 11:3–4 (2003), 323–333.
45. [45] Di Rosa, M., Malaguarnera, M., Nicoletti, F., Malaguernera, L., Vitamin D3: a helpful immuno-modulator. Immunology 134 (2011), 123–139.
46. [46] Griffin, M.D., Lutz, W., Phan, V.A., Bachman, L.A., McKean, D.J., Kumar, R., Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:12 (2001), 6800–6805.
47. [47] Almerighi, C., Sinistro, A., Cavazza, A., Ciaprini, C., Rocchi, G., Bergamini, A., 1Alpha, 25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes. Cytokine 45:3 (2009), 190–197.
48. [48] Aranow, C., Vitamin D and the immune system. J. Invest. Med. 59:6 (2011), 881–886.
49. [49] Penna, G., Roncari, A., Amuchastegui, S., Daniel, K.C., Berti, E., Colonna, M., Adorini, L., Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4 + Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood(10), 2005, 3490–3497 (15,106).
50. [50] van der Aar, A.M., Sibiryak, D.S., Bakdash, G., van Capel, T.M., van der Kleij, H.P., Opstelten, D.J., Teunissen, M.B., Kapsenberg, M.L., de Jong, E.C., Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. J. Allergy Clin. Immunol. 127:6 (2011), 1532–1540.
51. [51] Chen, S., Sims, G.P., Chen, X.X., Gu, Y.Y., Chen, S., Lipsky, P.E., Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol.(3), 2007, 1634–1647 (1,179).
52. [52] Barragan, M., Good, M., Kolls, J.K., Regulation of dendritic cell function by Vitamin D. Nutrients(9), 2015, 8127–8151 (21;7).
53. [53] Scolletta, S., Colletti, M., Di Luigi, L., Crescioli, C., Vitamin D receptor agonists target CXCL10: new therapeutic tools for resolution of inflammation. Mediators Inflamm., 2013, 2013, 876319.
54. [54] Nussinovitch, U., Shoenfeld, Y., Autoimmunity and heart diseases: pathogenesis and diagnostic criteria. Arch. Immunol. Ther. Exp. 57 (2009), 95–104.
55. [55] Fairweather, D., Frisancho-Kiss, S., Rose, N.R., Sex differences in autoimmune disease from a pathologic perspective. Am. J. Pathol. 173:3 (2008), 600–609.
56. [56] Teuscher, C., Noubade, R., Spach, K., McElvany, B., Bunn, J.Y., Fillmore, P.D., Zachary, J.F., Blankenhorn, E.P., Evidence that the Y chromosome influences autoimmune disease in male and female mice. Proc. Natl. Acad. Sci. U. S. A. 103:21 (2006), 8024–8029.
57. [57] Arnold, A.P., Chen, X., What does the four core genotypes mouse model tell us about sex differences in the brain and other tissues?. Front. Neuroendocrinol. 30 (2009), 1–9.
58. [58] Renaudineau, Y., Youinou, P., Epigenetics and autoimmunity, with special emphasis on methylation. Keio J. Med. 60:1 (2011), 10–16.
59. [59] Nussinovitch, U., Shoenfeld, Y., The role of gender and organ specific autoimmunity. Autoimmun. Rev. 11:6–7 (2012), A377–85.
60. [60] Greer, J.M., Csurhes, P.A., Pender, M.P., McCombe, P.A., Effect of gender on T-cell proliferative responses to myelin proteolipid protein antigens in patients with multiple sclerosis and controls. J. Autoimmun. 22 (2004), 345–352.
61. [61] Ngo, S.T., Steyn, F.J., McCombe, P.A., Gender differences in autoimmune disease. Front. Neuroendocrinol. 35:3 (2014), 347–369.
62. [62] McCombe, P.A., Greer, J.M., Sexual dimorphism in the immune system. Rose, N.R., Mackay, I.R., (eds.) The Autoimmune Diseases, 2013, Academic Press, 319–328.
63. [63] Lleo, A., Battezzati, P.M., Selmi, C., Gershwin, M.E., Podda, M., Is autoimmunity a matter of sex?. Autoimmun. Rev. 7:8 (2008), 626–630.
64. [64] Nalbandian, G., Kovats, S., Understanding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells. Immunol. Res. 31 (2005), 91–106.
65. [65] Calabrese, L.H., Kleiner, S.M., Barna, B.P., Skibinski, C.I., Kirkendall, D.T., Lahita, R.G., Lombardo, J.A., The effects of anabolic steroids and strength training on the human immune response. Med. Sci. Sports Exerc. 21 (1989), 386–392.
66. [66] Fujii, H., Nawa, Y., Tsuchiya, H., Matsuno, K., Fukumoto, T., Fukuda, S., Kotani, M., Effect of a single administration of testosterone on the immune response and lymphoid tissues in mice. Cell. Immunol. 20:2 (1975), 315–326.
67. [67] Duan, R.S., Link, H., Xiao, B.G., Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats. J. Clin. Immunol. 23 (2003), 100–106.
68. [68] Sakiani, S., Olsen, N.J., Kovacs, W.J., Gonadal steroids and humoral immunity. Nat. Rev. Endocrinol. 9:1 (2013), 56–62.
69. [69] Sthoeger, Z.M., Chiorazzi, N., Lahita, R.G., Regulation of the immune response by sex hormones. I. In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation. J. Immunol. 141:1 (1988), 91–98.
70. [70] Wyle, F.A., Kent, J.R., Immunosuppression by sex steroid hormones. The effect upon PHA- and PPD-stimulated lymphocytes. Clin. Exp. Immunol. 27:3 (1977), 407–415.
71. [71] Marshall-Gradisnik, S., Weatherby, R.P., Deakin, G.B., Coutts, R.A., Meir, R., Connellan, P., Stevenson, L.M., Rogerson, S., Zhou, S., Natural killer cell activity following 6 weeks of strength training in healthy young males with/without testosterone enanthate adminstration. J. Exerc. Sci. Fit. 6 (2008), 106–114.
72. [72] Hirota, Y., Suzuki, T., Chazono, Y., Bito, Y., Humoral immune responses characteristic of testosterone-propionate-treated chickens. Immunology 30:3 (1976), 341–348.
73. [73] McCarthy, M., The gender gap in autoimmune disease. Lancet, 356(9235), 2000, 1088.
74. [74] McCombe, P.A., Greer, J.M., Mackay, I.R., Sexual dimorphism in autoimmune disease. Curr. Mol. Med. 9:9 (2009), 1058–1079.
75. [75] Roubinian, J.R., Papoian, R., Talal, N., Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J. Clin. Invest. 59:6 (1977), 1066–1070.
76. [76] Giltay, E.J., van Schaardenburg, D., Gooren, L.J., Popp-Snijders, C., Dijkmans, B.A., Androgens and ankylosing spondylitis: a role in the pathogenesis?. Ann. N. Y. Acad. Sci. 22:876 (1999), 340–364.
77. [77] van Vollenhoven, R.F., Engleman, E.G., McGuire, J.L., An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arth. Rheum. 37:9 (1994), 1305–1310.
78. [78] van Vollenhoven, R.F., Park, J.L., Genovese, M.C., West, J.P., McGuire, J.L., A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 8:3 (1999), 181–187.
79. [79] Chang, D.M., Lan, J.L., Lin, H.Y., Luo, S.F., Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 46 (2002), 2924–2927.
80. [80] Deroo, B.J., Korach, K.S., Estrogen receptors and human disease. J. Clin. Invest. 116:3 (2006), 561–570.
81. [81] Zandman-Goddard, G., Peeva, E., Shoenfeld, Y., Gender and autoimmunity. Autoimmun. Rev. 6:6 (2007), 366–372.
82. [82] Smithson, G., Couse, J.F., Lubahn, D.B., Korach, K.S., Kincade, P.W., The role of estrogen receptors and androgen receptors in sex steroid regulation of B lymphopoiesis. J. Immunol.(1), 1998, 27–34 (1,161).
83. [83] Grimaldi, C.M., Cleary, J., Dagtas, A.S., Moussai, D., Diamond, B., Estrogen alters thresholds for B cell apoptosis and activation. J. Clin. Invest. 109:12 (2002), 1625–1633.
84. [84] Huber, S.A., Kuppermanm, J., Newell, M.K., Hormonal regulation of CD4(+) T-cell responses in coxsackievirus B3-induced myocarditis in mice. J. Virol. 73 (1999), 4689–4695.
85. [85] Fairweather, D., Cihakova, D., Alternatively activated macrophages in infection and autoimmunity. J. Autoimmun. 33 (2009), 222–230.
86. [86] Gilmore, W., Weiner, L.P., Correale, J., Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. J. Immunol.(1), 1997, 446–451 (1,158).
87. [87] Soldan, S.S., Alvarez Retuerto, A.I., Sicotte, N.L., Voskuhl, R.R., Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J. Immunol. 171 (2003), 6267–6274.
88. [88] Rubtsov, A.V., Rubtsova, K., Kappler, J.W., Marrack, P., Genetic and hormonal factors in female-biased autoimmunity. Autoimmun. Rev. 9 (2010), 494–498.
89. [89] Lista, P., Straface, E., Brunelleschi, S., Franconi, F., Malorni, W., On the role of autophagy in human diseases: a gender perspective. J. Cell. Mol. Med. 15:7 (2011), 1443–1457.
90. [90] Martel, C., Huynh le, H., Garnier, A., Ventura-Clapier, R., Brenner, C., Inhibition of the mitochondrial permeability transition for cytoprotection: direct versus indirect mechanisms. Biochem. Res. Int., 2012, 2012, 213403.
91. [91] Chen, X.L., Kunsch, C., Induction of cytoprotective genes through Nrf2/antioxidant response element pathway: a new therapeutic approach for the treatment of inflammatory diseases. Curr. Pharm. Des. 10 (2004), 879–891.
92. [92] Ho, H.N., Wu, M.Y., Chen, H.F., Chao, K.H., Yang, Y.S., Huang, S.C., Lee, T.Y., 3rd, Gill, In vivo CD3 + CD25+ lymphocyte subpopulation is down-regulated without increased serum-soluble interleukin-2 receptor (sIL-2R) by gonadotropin releasing hormone agonist (GnRH-a). Am. J. Reprod. Immunol. 33 (1995), 134–139.
93. [93] Al Maini, M., Adelowo, F., Al Saleh, J., Al Weshahi, Y., Burmester, G.R., Cutolo, M., Flood, J., March, L., McDonald-Blumer, H., Pile, K., Pineda, C., Thorne, C., Kvien, T.K., The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumaticand Musculoskeletal Diseases. Clin. Rheumatol. 34 (2015), 819–829.
94. [94] Lundberg, I.E., Nader, G.A., Molecular effects of exercise in patients with inflammatory rheumatic disease. Nat. Clin. Pract. Rheumatol. 4:11 (2008), 597–604.
95. [95] Vos, T., Flaxman, A.D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J.A., Abdalla, S., Aboyans, V., Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet 380:9859 (2013), 2163–2196.
96. [96] Oliver, J.E., Silman, A.J., Why are women predisposed to autoimmune rheumatic diseases?. Arthritis Res. Ther. 11 (2009), 252–260.
97. [97] Cutolo, M., Capellino, S., Sulli, A., Serioli, B., Secchi, M.E., Villaggio, B., Straub, R.H., Estrogens and autoimmune diseases. Ann. N. Y. Acad. Sci. 1089 (2006), 538–547.
98. [98] Borchers, A.T., Naguwa, S.M., Shoenfeld, Y., Gershwin, M.E., The geoepidemiology of systemic lupus erythematosus. Autoimmun. Rev. 9 (2010), A277–287.
99. [99] Peeva, E., Zouali, M., Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol. Lett.(2), 2005, 123–143 (15,101).
100. [100] Zandman-Goddard, G., Peeva, E., Shoenfeld, Y., Gender and autoimmunity. Autoimmun. Rev. 6:6 (2007), 366–372.
101. [101] Yacoub Wasef, S.Z., Gender differences in systemic lupus erythematosus. Gend Med. 1:1 (2004), 12–17.
102. [102] Roubinian, J.R., Talal, N., Greenspan, J.S., Goodman, J.R., Siiteri, P.K., Effect of castration and sex hormone treatment on survival: anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J. Exp. Med.(6), 1978, 1568–1583 (1,147).
103. [103] Pierdominici, M., Ortona, E., Estrogen impact on autoimmunity onset and progression: the paradigm of systemic lupus erythematosus. Int. Trends Immun. 1 (2013), 24–34.
104. [104] Maselli, A., Conti, F., Alessandri, C., Colasanti, T., Barbati, C., Vomero, M., Ciarlo, L., Patrizio, M., Spinelli, F.R., Ortona, E., Valesini, G., Pierdominici, M., Low expression of estrogen receptor β in T lymphocytes and high serum levels of anti-estrogen receptor α antibodies impact disease activity in female patients with systemic lupus erythematosus. Biol. Sex Differ., 12(7), 2016, 3.
105. [105] Sequeira, J.F., Keser, G., Greenstein, B., Wheeler, M.J., Duarte, P.C., Khamashta, M.A., Hughes, G.R., Systemic lupus erythematosus: sex hormones in male patients. Lupus 2:5 (1993), 315–317.
106. [106] Sasano, H., Miki, Y., Nagasaki, S., et al. In situ estrogenproduction and its regulation in human breast carcinoma: from endocrinology to intracrinology. Pathol. Int. 59 (2009), 777–789.
107. [107] Krishnan, A.V., Swami, S., Peng, L., Wang, J., Moreno, J., Feldman, D., Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 5 (2010), 32–34.
108. [108] Ortona, E., Pierdominici, M., Maselli, A., Veroni, C., Aloisi, F., Shoenfeld, Y., Sex-based differences in autoimmune diseases. Ann. Ist Super Sanità 2:52 (2016), 205–212.
109. [109] Cutolo, M., Sulli, A., Capellino, S., Villaggio, B., Montagna, P., Seriolo, B., Straub, R.H., Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 13 (2004), e635–e638.
110. [110] Folomeev, M., Dougados, M., Beaune, J., Kouyoumdjian, J.C., Nahoul, K., Amor, B., Alekberova, Z., Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus 1 (1992), 191–195.
111. [111] Shi-Wen, X., Panesar, M., Vancheeswaran, R., Mason, J., Haskard, D., Black, C., Olsen, I., Abraham, D., Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts. Effects of interferon-gamma, tumor necrosis alpha and estrogen. Arthritis Rheum., 37, 1994, 168997.
112. [112] Vacca, A., Cormier, C., Mathie, A., Kahan, A., Allanore, Y., Vitamin D levels and potential impact in systemic sclerosis. Clin. Exp. Rheumatol. 29 (2011), 1024–1031.
113. [113] Chifflot, H., Fautrel, B., Sordet, C., Chatelus, E., Sibilia, J., Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin. Arthritis Rheum. 37 (2008), e223–e235.
114. [114] LeRoy, E.C., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Jr, T., Rowell, N., Wollheim, F., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15 (1988), e202–e205.
115. [115] Straub, R.H., Zeuner, M., Lock, G., Schölmerich, J., Lang, B., High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severesystemic sclerosis. Br. J. Rheumatol. 36 (1997), e426–e432.
116. [116] Stolwijk, C., Boonen, A., van Tubergen, A., Reveille, J.D., Epidemiology of spondyloarthritis. Rheum. Dis. Clin. North 38:3 (2012), 441–476.
117. [117] Kennedy, L.G., Will, R., Calin, A., Sex ratio in the spondyloarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset. J. Rheumatol. 20:11 (1993), 1900–1904.
118. [118] Giltay, E.J., Popp-Snijders, C., van Schaardenburg, D., Dekker-Saeys, B.J., Gooren, L.J., Dijkmans, B.A., Serum testosterone levels are not elevated in patients with ankylosing spondylitis. J. Rheumatol. 25 (1998), 2389–2394.
119. [119] Giltay, E.J., van Schaardenburg, D., Gooren, L.J., Popp-Snijders, C., Dijkmans, B.A., Androgens and ankylosing spondylitis: a role in the pathogenesis?. Ann. N. Y. Acad. Sci. 876 (1999), 340–364.
120. [120] Gooren, L.J., Giltay, E.J., van Schaardenburg, D., Dijkmans, B.A., Gonadal and adrenal sex steroids in ankylosing spondylitis. Rheum. Dis. Clin. North Am. 26 (2000), 969–987.
121. [121] Straub, R.H., Struharova, S., Scholmerich, J., Harle, P., No alternations of serum levels of adrenal and gonadal hormones in patients with ankylosing spondylitis. Clin. Exp. Rheumatol. 28:suppl (2002), 852–859.
122. [122] Capkova, J., Ivanyi, P., Rehakova, Z., Sexual dimorphism, but not testosterone itself, is responsible for ankylosing enthesitis of the ankle in B10. BR (H-2k) male mice. Ann. Rheum. Dis. 65 (2006), 130–132.
123. [123] Scarpa, R., Atteno, M., Peluso, R., Costa, L., Padula, S., Di Minno, D., Caso, F., Iervolino, S., Vitiello, M., Del Puente, A., Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer. J. Clin. Rheumatol. 17:4 (2011), 169–172.
124. [124] Gracey, E., Sexual dimorphism in the th17 signature of ankylosing spondylitis. Arthritis Rheumatol. 68:3 (2016), 679–689.
125. [125] Meijer, J.M., Meiners, P.M., Vissink, A., Spijkervet, F.K., Abdulahad, W., Kamminga, N., Brouwer, E., Kallenberg, C.G., Bootsma, H., Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumtol. 62:4 (2010), 60–68.
126. [126] Mavragani, C.P., Moutsopoulos, H.M., The geoepidemiology of Sjögren's syndrome. Autoimmun. Rev., 9, 2010 (A305e10).
127. [127] Arakaki, R., Ishimaru, N., Hayashi, Y., Immunotherapeutic targets in estrogen deficiency-dependent Sjogren's syndrome-related manifestations. Immunotherapy 2 (2010), 339–346.
128. [128] Hayashi, Y., Arakaki, R., Ishimaru, N., Apoptosis and estrogen deficiency in primary Sjogren syndrome. Curr. Opin. Rheumatol. 16 (2004), 522–526.
129. [129] Ishimaru, N., Arakaki, R., Watanabe, M., Kobayashi, M., Miyazaki, K., Hayashi, Y., Development of autoimmune exocrinopathy resembling Sjogren's syndrome in estrogen-deficient mice of healthy background. Am. J. Pathol. 163 (2003), 1481–1490.
130. [130] Ishimaru, N., Saegusa, K., Yanagi, K., Haneji, N., Saito, I., Hayashi, Y., Estrogen deficiency accelerates autoimmune exocrinopathy in murine Sjogren's syndrome through fas-mediated apoptosis. Am. J. Pathol. 155 (1999), 173–181.
131. [131] Shim, G.J., Warner, M., Kim, H.J., Andersson, S., Liu, L., Ekman, J., Imamov, O., Jones, M.E., Simpson, E.R., Gustafsson, J.A., Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 12628–12633.
132. [132] Sullivan, D.A., Tearful relationships? Sex, hormones, the lacrimal gland, and aqueous-deficient dry eye. Ocul. Surf. 2 (2004), 92–123.
133. [133] Takahashi, M., Ishimaru, N., Yanagi, K., Haneji, N., Saito, I., Hayashi, Y., High incidence of autoimmune dacryoadenitis in male non-obese diabetic (NOD) mice depending on sex steroid. Clin. Exp. Immunol. 109 (1997), 555–561.
134. [134] Affinito, P., Di Spiezio Sardo, A., Di Carlo, C., Sammartino, A., Tommaselli, G.A., Bifulco, G., Loffredo, A., Loffredo, M., Nappi, C., Effects of hormone replacement therapy on ocular function in postmenopause. Menopause 10 (2003), 482–487.
135. [135] Guaschino, S., Grimaldi, E., Sartore, A., Mugittu, R., Mangino, F., Bortoli, P., Pensiero, S., Vinciguerra, A., Perissutti, P., Visual function in menopause: the role of hormone replacement therapy. Menopause 10 (2003), 53–57.
136. [136] Mostafa, S., Seamon, V., Azzarolo, A.M., Influence of sex hormones and genetic predisposition in Sjogren's syndrome: a new clue to the immunopathogenesis of dry eye disease. Exp. Eye Res. 96 (2012), 88–97.
137. [137] Iwasa, A. aromatase controls sjögren syndromee like lesions through monocyte chemotactic protein-1 in target organ and adipose tissue associated macrophages. Am. J. Pathol., 2015, 185.
138. [138] Verthelyi, D., Ansar Ahmed, S., Characterization of estrogen-induced autoantibodies to cardiolipin in non-autoimmune mice. J. Autoimmun. 10 (1997), 115–125.
139. [139] Orbach, H., Zandman-Goddard, G., Amital, H., Barak, V., Szekanecz, Z., Szucs, G., Danko, K., Nagy, E., Csepany, T., Carvalho, J.F., Doria, A., Shoenfeld, Y., Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels inautoimmune diseases. Ann. N. Y. Acad. Sci. 1109 (2007), 385–400.
140. [140] Jara, L.J., Medina, G., Vera-Lastra, O., Barile, L., The impact of gender on clinical manifestations of primary antiphospholipid syndrome. Lupus 14:8 (2005), 607–612.
141. [141] de Carvalho, J.F., Influence of gender on the clinical and laboratory spectra of patients with primary antiphospholipid syndrome. Rheumatol. Int. 31:5 (2011), 647–650.
142. [142] Merlino, L.A., Curtis, J., Mikuls, T.R., Cerhan, J.R., Criswell, L.A., Saag, K.G., Iowa women's health study Vitamin D intake is inversely associated with rheumatoid arthritis: results from the iowa women's health study. Arthritis Rheumatol. 50:1 (2004), 72–77.
143. [143] Patel, S., Farragher, T., Berry, J., Bunn, D., Silman, A., Symmons, D., Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheumatol. 56 (2007), 2143–2149.
144. [144] Cutolo, M., Otsa, K., Laas, K., Yprus, M., Lehtme, R., Secchi, M.E., Sulli, A., Paolino, S., Seriolo, B., Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: northern versus Southern Europe. Clin. Exp. Rheumatol. 24 (2006), 702–704.
145. [145] Arnson, Y., Amital, H., Shoenfeld, Y., Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann. Rheum. Dis. 66:9 (2007), 1137–1142.
146. [146] Cutolo, M., Vitamin D and autoimmune rheumatic diseases. Rheumatology (Oxford) 48:3 (2009), 210–212.
147. [147] Agrawal, T., Gupta, G.K., Agrawal, D.K., Vitamin D supplementation reduces airway hyperresponsiveness and allergic airway inflammation in a murine model. Clin. Exp. Allergy 43:6 (2013), 672–683.
148. [148] Borba, V.Z., Vieira, J.G., Kasamatsu, T., Radominski, S.C., Sato, E.I., Lazaretti-Castro, M., Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos. Int. 20 (2009), 427–443.
149. [149] Kamen, D.L., Cooper, G.S., Bouali, H., Shaftman, S.R., Hollis, B.W., Gilkeson, G.S., Vitamin D deficiency in systemic lupus erythematosus. Autoimmun. Rev. 50 (2006), 72–77.
150. [150] Squance, M.L., Reeves, G.E., Tran, H.A., Vitamin D levels are associated with expression of SLE, but not flare frequency. Int. J. Rheumatol., 2014, 2014, 362834.
151. [151] Birmingham, D.J., Hebert, L.A., Song, H., Noonan, W.T., Rovin, B.H., Nagaraja, H.N., Yu, C.Y., Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus 21:8 (2012), 855–864.
152. [152] Borba, V.Z., Vieira, J.G., Kasamatsu, T., Radominski, S.C., Sato, E.I., Lazaretti-Castro, M., Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos. Int. 20 (2009), 427–443.
153. [153] Ruiz-Irastorza, G., Egurbide, M.V., Olivares, N., Martinez-Berriotxoa, A., Aguirre, C., Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 47 (2008), 920–923.
154. [154] Kim, H.A., Sung, J.M., Jeon, J.Y., Yoon, J.M., Suh, C.H., Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus. Rheumatol. Int. 31 (2011), 1189–1194.
155. [155] Wright, T.B., Shults, J., Leonard, M.B., Zemel, B.S., Burnham, J.M., Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J. Pediatr. 155 (2009), 260–266.
156. [156] Cutolo, M., Otsa, K., Yprus, M., Seriolo, B., Vitamin D and rheumatoid arthritis: comment on the letter by Nielen et al. Arthritis Rheum. 56:5 (2007), 1719–1720.
157. [157] Nielen, M.M., van Schaardenburg, D., Lems, W.F., van de Stadt, R.J., de Koning, M.H., Reesink, H.W., Habibuw, M.R., van der Horst-Bruinsma, I.E., Twisk, J.W., Dijkmans, B.A., Vitamin D deficiency does not increase the risk of rheumatoid arthritis: comment on the article by Merlino et al. Arthritis Rheum. 54:11 (2006), 3719–3720.
158. [158] Constenbader, K.H., Chang, S.C., Laden, F., Puett, R., Karlson, E.W., Geographic variation in rheumatoid arthritis incidence among women in the United States. Arch. Intern. Med.(15), 2008, 1664–1670 (11,168).
159. [159] Arkema, E.V., Hart, J.E., Bertrand, K.A., Laden, F., Grodstein, F., Rosner, B.A., Karlson, E.W., Costenbader, K.H., Exposure to ultraviolet-B and risk of developing rheumatoid arthritis among women in the Nurses’ HealthStudy. Ann. Rheum. Dis. 72:4 (2013), 506–511.
160. [160] Mouterde, G., Lukas, C., Logeart, I., Flipo, R.M., Rincheval, N., Daurès, J.P., Combe, B., Predictors of radiographic progression in the ESPOIR cohort: the season of first symptoms may influence theshort-term outcome in early arthritis. Ann. Rheum. Dis. 70:7 (2011), 1251–1256.
161. [161] Cutolo, M., Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat. Rev. Rheumatol.(9), 2011, 500–502 (2;7).
162. [162] Park, Y.E., Kim, B.H., Lee, S.G., Park, E.K., Park, J.H., Lee, S.H., Kim, G.T., Vitamin D status of patients with early inflammatory arthritis. Clin. Rheumatol. 34:2 (2015), 239–246.
163. [163] Rossini, M., Maddali Bongi, S., La Montagna, G., Minisola, G., Malavolta, N., Bernini, L., Cacace, E., Sinigaglia, L., Di Munno, O., Adami, S., Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res. Ther., 12(6), 2010, R216.
164. [164] Haque, U.J., Bartlett, S.J., Relationships among vitamin D, disease activity, pain and disability in rheumatoid arthritis. Clin. Exp. Rheumatol. 28:5 (2010), 745–747.
165. [165] Turhanoğlu, A.D.1, Güler, H., Yönden, Z., Aslan, F., Mansuroglu, A., Ozer, C., The relationship between vitamin D and disease activity and functional health status in rheumatoid arthritis. Rheumatol. Int. 31:7 (2011), 911–914.
166. [166] Kerr, G.S., Sabahi, I., Richards, J.S., Caplan, L., Cannon, G.W., Reimold, A., Thiele, G.M., Johnson, D., Mikuls, T.R., Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity. J. Rheumatol. 38:1 (2011), 53–59.
167. [167] Andjelkovic, Z., Vojinovic, J., Pejnovic, N., Popovic, M., Dujic, A., Mitrovic, D., Pavlica, L., Stefanovic, D., Disease modifying and immunomodulatory effects of high dose 1 alphaOH D3 in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 17 (1999), 453–456.
168. [168] Durmu, B., Altay, Z., Baysal, O., Ersoy, Y., Does vitamin D affect disease severity in patients with ankylosing spondylitis?. Chin. Med. J. (Engl.) 125:14 (2012), 2511–2515.
169. [169] Zhao, S., Duffield, S.J., Moots, R.J., Goodson, N.J., Systematic review of association between vitamin D levels and susceptibility and diseaseactivity of ankylosing spondylitis. Rheumatology (Oxford) 53:9 (2014), 1595–1603.
170. [170] Caramaschi, P., Dalla, G.A., Ruzzenente, O., Volpe, A., Ravagnani, V., Tinazzi, I., Barausse, G., Bambara, L.M., Biasi, D., Very low levels of vitamin D in systemic sclerosis patients. Clin. Rheumatol. 12 (2010), 1419–1425.
171. [171] Rios, F.R., Fernandez, R.C., Callejas Rubio, J.L., Ortego, C.N., Vitamin D deficiency in a cohort of patients with systemic scleroderma from the south of Spain. J. Rheumatol., 37, 2010, 1355.
172. [172] Vacca, A., Cormier, C., Piras, M., Mathieu, A., Kahan, A., Allanore, Y., Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J. Rheumatol. 36 (2009), 1924–1929.
173. [173] Braun-Moscovici, Y., Furst, D.E., Markovits, D., Rozin, A., Clements, P.J., Nahir, A.M., Balbir-Gurman, A., Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosis. J. Rheumatol. 35 (2008), 2201–2205.
174. [174] Gambichler, T., Chrobok, I., Höxtermann, S., Kreuter, A., Significantly decreased serum 25-hydroxyvitamin d levels in a large german systemic sclerosis cohort. J. Rheumatol. 38 (2011), 2492–2493.
175. [175] Zerr, P., Vollath, S., Palumbo-Zerr, K., Tomcik, M., Huang, J., Distler, A., Beyer, C., Dees, C., Gela, K., Distler, O., Schett, G., Distler, J.H., Vitamin D receptor regulates TGF-β signalling in systemic sclerosis. Ann. Rheum. Dis., 74, 2015, e20.
176. [176] Bang, B., Asmussen, K., Sørensen, O.H., Oxholm, P., Reduced 25-hydroxyvitamin D levels in primary Sjögren's syndrome. Correlations to disease manifestations. Scand. J. Rheumatol. 28:3 (1999), 80–83.
177. [177] Erten, Ş., Şahin, A., Altunoğlu, A., Gemcioğlu, E., Koca, C., Comparison of plasma vitamin D levels in patients with Sjögren's syndrome and healthy subjects. Int. J. Rheumatol. Dis. 18:1 (2015), 0–5.
178. [178] Baldini, C., Delle Sedie, A., Luciano, N., Pepe, P., Ferro, F., Talarico, R., Tani, C., Mosca, M., Vitamin D in early primary Sjogren's syndrome: does it play a role in influencing disease phenotypes?. Rheumatol. Int. 4:8 (2014), 159–164.
179. [179] Piantoni, S., Andreolim, L., Allegri, F., Meroni, P.L., Tincani, A., Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. Reumatismo(5), 2012, 307–313 (11, 64).
180. [180] Agmon-Levin, N., Blank, M., Zandman-Goddard, M., Orbach, H., Meroni, P.L., Tincani, A., Doria, A., Cervera, R., Miesbach, W., Stojanovich, L., Barak, V., Porat-Katz, B.S., Amital, H., Shoenfeld, Y., Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann. Rheum. Dis. 70 (2011), 145–150.
181. [181] Zold, E., Szodoray, P., Gaal, J., Kappelmayer, J., Csathy, L., Gyimesi, E., Zeher, M., Szegedi, G., Bodolay, E., Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res. Ther., 10(5), 2008, R123.
182. [182] Zold, E., Szodoray, P., Kappelmayer, J., Gaal, J., Csathy, L., Barath, S., Gyimesi, E., Hajas, A., Zeher, M., Szegedi, G., Bodolay, E., Impaired regulatory T-cell homeostasis due to vitamin D deficiency in undifferentiated connective tissue disease. Scand. J. Rheumatol. 39:6 (2010), 490–497.
183. [183] Mitra, R., Adverse effects of corticosteroids on bone metabolism: a review. PM R 3:5 (2011), 466–471 (quiz 471).
184. [184] Godschalk, M., Levy, J.R., Downs, R.W. Jr., Glucocorticoids decrease vitamin D receptor number and gene expression in human osteosarcoma cells. J. Bone Miner. Res. 7:1 (1992), 1–7.
185. [185] Levin, A.D., Wadhera, V., Leach, S.T., Woodhead, H.J., Lemberg, D.A., Mendoza-Cruz, A.C., Day, A.S., Vitamin D deficiency in children with inflammatory bowel disease. Dig. Dis. Sci. 56:3 (2011), 30–36.
186. [186] Shi, D., Yang, D., Yan, B., Dexamethasone transcriptionally increases the expression of the pregnane X receptor and synergistically enhances pyrethroid esfenvalerate in the induction of cytochrome P450 3A23. Biochem. Pharmacol. 80:8 (2010), 1274–1283.
187. [187] Zhang, B., Xie, W., Krasowski, M.D., PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9 (2008), 1695–1709.
188. [188] Pascussi, J.M., Robert, A., Nguyen, M., Walrant-Debray, O., Garabedian, M., Martin, P., Pineau, T., Saric, J., Navarro, F., Maurel, P., Vilarem, M.J., Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J. Clin. Invest. 115:1 (2005), 77–86.
189. [189] Zhai, Y., Pai, H.V., Zhou, J., Amico, J.A., Vollmer, R.R., Xie, W., Activation of pregnane X receptor disrupts glucocorticoid and mineralocorticoid homeostasis. Mol. Endocrinol. 21:1 (2007), 38–47.
190. [190] O'Leary, T.J., Jones, G., Yip, A., Lohnes, D., Cohanim, M., Yendt, E.R., The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N. Engl. J. Med. 315:12 (1986), 727–730.
191. [191] Huisman, A.M., White, K.P., Algra, A., Harth, M., Vieth, R., Jacobs, J.W., Bijlsma, J.W., Bell, D.A., Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J. Rheumatol. 28:11 (2001), 2535–2539.
192. [192] Ebert, R., Jovanovic, M., Ulmer, M., Schneider, D., Meissner-Weigl, J., Adamski, J., Jakob, F., Down-Regulation by nuclear factor kB of human 25-Hydroxyvitamin D3 1α-Hydroxylase promoter. Mol. Endocrinol. 18:10 (2016), 2440–2450.
193. [193] Huisman, A.M., White, K.P., Algra, A., Harth, M., Vieth, R., Jacobs, J.W., Bijlsma, J.W., Bell, D.A., Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J. Rheumatol. 28:11 (2001), 2535–2539.
194. [194] Ebert, Regina, Jovanovic, Marlena, Ulmer, Matthias, SCHNEIDER, D.O.R.I.S., MEISSNER-WEIGL, J.U.T.T.A., ADAMSKI, J.E.R.Z.Y., JAKOB, F.R.A.N.Z., Down-Regulation by nuclear factor kB of human 25-Hydroxyvitamin D3 1α-Hydroxylase promoter. Mol. Endocrinol. 18:10 (2004), 2440–2450.
195. [195] Reichel, H., Gruessinger, A., Knehans, A., Kuehn, K., Schmidt- Gayk, H., Ritz, E., Long-term therapy with cyclosporin A does not influence serum concentrations of vitamin D metabolites in patients with multiple sclerosis. Clin. Invest. 70 (1992), 595–599.
196. [196] Filipova, Jean Jeanov, Zlatkova, Borelli Kirilov, Dimitrov, Emil Paskalev, Svinarov, Dobrin, Relationship between vitamin D status and immunosuppressive therapy in kidney transplant Recipients. Biotechnol. Biotechnol. Equip. 29:2 (2015), 331–335.
197. [197] Mok, C.C., Tong, K.H., To, C.H., Siu, Y.P., Au, T.C., Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. 68:2 (2005), 13–817.
198. [198] Lee, C.T., Ng, H.Y., Lien, Y.H., et al. Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism. Am. J. Nephrol. 34:1 (2011), 87–94.
199. [199] Grenet, O., Bobadilla, M., Chibout, S.D., Steiner, S., Evidence for the impairment of the vitamin D activation pathway by cyclosporine A. Biochem. Pharmacol. 59:3 (2000), 267–272.
200. [200] Baker, J.F., Baker, D.G., Toedter, G., Shults, J., Von Feldt, J.M., Leonard, M.B., Associations between vitamin D, disease activity, and clinical response to therapy in rheumatoid arthritis. Clin. Exp. Rheumatol. 30:5 (2012), 58–64.
201. [201] Welsh, P., Peters, M.J., McInnes, I.B., Lems, W.F., Lips, P.T., McKellar, G., Knox, S., Michael Wallace, A., Dijkmans, B.A., Nurmohamed, M.T., Sattar, N., Vitamin D deficiency is common in patients with RA and linked to disease activity, but circulating levels are unaffected by TNFα blockade: results from a prospective cohort study. Ann. Rheum. Dis. 70:6 (2011), 1165–1167.
202. [202] Hasan, E., Olusi, S., Al-Awadhi, A., Mokaddem, K., Sharma, P., George, S., Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2 7, and 10 in patients with rheumatoid arthritis. Biologics 6 (2012), 31–35.
203. [203] De Paepe, B., Zschüntzsch, J., Scanning for therapeutic targets within the cytokine network of idiopathic inflammatory myopathies. Int. J. Mol. Sci. 16:8 (2015), 18683–18713.
204. [204] Grundtman, C., Malmstrom, V., Lundberg, I.E., Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res. Ther. 9 (2007), 208–220.
205. [205] Rayavarapu, S., Coley, W., Kinder, T.B., Nagaraju, K., Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skeletal Muscle, 3, 2013 (article 13).
206. [206] Dalakas, M.C., Polymyositis, dermatomyositis, and inclusion-body myositis. N. Engl. J. Med. 325:21 (1991), 1487–1498.
207. [207] Dalakas, M.C., Hohlfeld, R., Polymyositis and dermatomyositis. Lancet 362:9388 (2003), 71–82.
208. [208] Welsh, P., Peters, M.J., Sattar, N., Is vitamin D in rheumatoid arthritis a magic bullet or a mirage? The need to improve the evidence base prior to calls for supplementation. Arthritis Rheumatol. 63:7 (2011), 1763–1769.
209. [209] Ritterhouse, L.L., Crowe, S.R., Niewold, T.B., Kamen, D.L., Macwana, S.R., Roberts, V.C., Dedeke, A.B., Harley, J.B., Scofield, R.H., Guthridge, J.M., James, J.A., Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 70 (2011), 1569–1574.
210. [210] Azali, P., Barbasso Helmers, S., Kockum, I., Olsson, T., Alfredsson, L., Charles, P.J., Piehl Aulin, K., Lundberg, I.E., Low serum levels of vitamin D in idiopathic inflammatory myopathies. Ann. Rheum. Dis. 72:4 (2013), 512–516.
211. [211] Nagaraju, K., Update on immunopathogenesis in inflammatory myopathies. Curr. Opin. Rheumatol. 13:6 (2001), 461–468.
212. [212] Tournadre, A., Miossec, P., Immunoregulation in idiopathic inflammatory myopathies: from dendritic cells to immature regenerating muscle cells. J. Rheumatol. 40:2 (2013), 110–112.
213. [213] de Padilla, C.M., Reed, A.M., Dendritic cells and the immunopathogenesis of idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 20:6 (2008), 669–674.
214. [214] Karthaus, N., van Spriel, A.B., Looman, M.W., Chen, S., Spilgies, L.M., Lieben, L., Carmeliet, G., Ansems, M., Adema, G.J., Vitamin D controls murine and human plasmacytoid dendritic cell function. J. Invest. Dermatol. 134:5 (2014), 1255–1264.
215. [215] Brosbøl-Ravnborg, A., Bundgaard, B., Höllsberg, P., Synergy betweenvitamin D (3) and Toll-like receptor agonists regulates human dendritic cell response during maturation. Clin. Dev. Immunol., 2013, 2013, 807971.
216. [216] Cutolo, M., Further emergent evidence for the vitamin D endocrine system involvement in autoimmune rheumatic disease risk and prognosis. Ann. Rheum. Dis. 72:4 (2013), 473–475.
217. [217] Kovats, S., Estrogen receptors regulate innate immune cells and signalling pathways. Cell. Immunol. 294:2 (2015), 63–69.
218. [218] Váncsa, A., Ponyi, A., Constantin, T., Zeher, M., Dankó, K., Pregnancy outcome in idiopathic inflammatory myopathy. Rheumatol. Int. 27:5 (2007), 435–439.
219. [219] Yang, M., Yang, L., Wang, X., Wang, Y., Wei, Y., Zhao, Y., Decline of plasmacytoid dendritic cells and their subsets in normal pregnancy are related with hormones. J. Reprod. Med. 60:9–10 (2015), 423–429.
220. [220] Hughes, G.C., Clark, E.A., Regulation of dendritic cells by female sex steroids: relevance to immunity and autoimmunity. Autoimmunity 40:6 (2007), 470–481.
221. [221] Seillet, C., Laffont, S., Tremollieres, F., Rouquie, N., Ribot, C., Arnal, J.F., Douin-Echinard, V., Gourdy, P., Guery, J.C., The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor alpha signaling. Blood 119 (2012), 454–464.
222. [222] Sereda, D., Werth, V.P., Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch. Dermatol. 142:1 (2006), 70–72.
223. [223] Aikawa, N.E., Sallum, A.M., Leal, M.M., Bonfá, E., Pereira, R.M., Silva, C.A., Menstrual and hormonal alterations in juvenile dermatomyositis. Clin. Exp. Rheumatol. 28:4 (2010), 571–575 (Epub 2010 Aug 31).
224. [224] de Souza, F.H., da Silva, C.A., Yamakami, L.Y., dos Santos Trindade Viana, V., Bonfá, E., Shinjo, S.K., Reduced ovarian reserve in patients with adult polymyositis. Clin. Rheumatol. 34 (2015), 1795–1799.
225. [225] da Silva, C.A.A., Moraes, A.J.P.M., Leal, M.M., Sallum, A.M.E., Bonfá, E., Borges, C.T.L.B., Hilário, M.O.E., Terreri, M.T., Ronchezel, M., Saito, O., Hallak, J., Reproductive health aspects in men with idiopathic inflammatory myopathy: a multicenter study. Rev. Bras. Reumatol. 49:6 (2009), 677–689.
226. [226] Kragt, J., van Amerongen, B., Killestein, J., Dijkstra, C., Uitdehaag, B., Polman, C., Lips, P., Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult. Scler. 15 (2009), 9–15.
227. [227] Nashold, F.E., Spach, K.M., Spanier, J.A., Hayes, C.E., Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J. Immunol. 183:6 (2009), 3672–3681.
228. [228] Crescioli, C., Sottili, M., Bonini, P., Cosmi, L., Chiarugi, P., Romagnani, P., Vannelli, G.B., Colletti, M., Isidori, A.M., Serio, M., Lenzi, A., Di Luigi, L., Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target. Eur. J. Cell Biol. 91:2 (2012), 139–149.
229. [229] Di Luigi, L., Sottili, M., Antinozzi, C., Vannelli, G.B., Romanelli, F., Riccieri, V., Valesini, G., Lenzi, A., Crescioli, C., The vitamin D receptor agonist BXL-01-0029 as a potential new pharmacological tool for the treatment of inflammatory myopathies. PLoS One(10), 2013, e77745 (30;8).
230. [230] Crescioli, C., Vitamin D receptor agonists: suitable candidates as novel therapeutic options in autoimmune inflammatory myopathy. BioMed Res. Int., 2014, 2014, 949730.
231. [231] Scolletta, S., Colletti, M., Di Luigi, L., Crescioli, C., Vitamin D receptor agonists target CXCL10: new therapeutic tools for resolution of inflammation. Mediators Inflamm., 2013, 2013, 876319.
232. [232] Sagrinati, C., Sottili, M., Mazzinghi, B., Borgogni, E., Adorini, L., Serio, M., Romagnani, P., Crescioli, C., Comparison between VDR analogs and current immunosuppressive drugs in relation to CXCL10 secretion by human renal tubular cells. Transpl. Int. 23:9 (2010), 914–923.
233. [233] Dalakas, M.C., Immunotherapy of myositis: issues, concerns and future prospects. Nat. Rev. Rheumatol. 6:3 (2010), 129–137.
234. [234] Miller, F.W., New approaches to the assessment and treatment of the idiopathic inflammatory my9pathies. Ann. Rheum. Dis. 71:2 (2012), i82–i85.
235. [235] Ernste, F.C., Reed, A.M., Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin. Proc. 88 (2013), 83–105.
236. [236] Wang, Y., Zhu, J., DeLuca, H.F., Where is the vitamin D receptor?. Arch. Biochem. Biophys. 1 (2012), 123–133.
237. [237] Girgis, C.M., Clifton-Bligh, R.J., Hamrick, M.W., Holick, M.F., Gunton, J.E., The roles of vitamin D in skeletal muscle: form, function, and metabolism. Endocr. Rev. 34 (2013), 33–83.
238. [238] Polly, P., Tan, T.C., The role of vitamin D in skeletal and cardiac muscle function. Front. Physiol., 16, 2014, 145.
239. [239] Lotz, B.P., Engel, A.G., Nishino, H., Stevens, J.C., Litchy, W.J., Inclusion body myositis. Observations in 40 patients. Brain 112 (1989), 727–747.
240. [240] Limaye, V.S., Lester, S., Blumbergs, P., Roberts-Thomson, P.J., Idiopathic inflammatory myositis is associated with a high incidence of hypertension and diabetes mellitus. Int. J. Rheum. Dis. 13:May (2) (2010), 132–137.
241. [241] Nasri, H., Behradmanesh, S., Maghsoudi, A.R., Ahmadi, A., Nasri, P., Rafieian-Kopaei, M., Efficacy of supplementary vitamin D on improvement of glycemic parameters in patients with type 2 diabetes mellitus; a randomized double blind clinical trial. J. Renal Inj. Prev. 3 (2013), 31–34.
242. [242] Boucher, B.J., Vitamin D insufficiency and diabetes risks. Curr. Drug Targets 12 (2011), 61–87.
243. [243] Zhu, G.D., Vitamin D analogs currently on the market and in development. Why Does Vitamin D Matter?, vol. 26, 2013, Bentham Science Publisher, 57–82.
244. [244] Feldman, D., Wesley Pike, J., Adams, J.S., Vitamin D. 3rd edition, 2011, Academic Press, London, UK.
245. [245] Marchiani, S., Bonaccorsi, L., Ferruzzi, P., Crescioli, C., Muratori, M., Adorini, L., Forti, G., Maggi, M., Baldi, E., The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J. Cancer Res. Clin. Oncol. 132:6 (2006), 408–416.
246. [246] Maggi, M., Crescioli, C., Morelli, A., Colli, E., Adorini, L., Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). J. Endocrinol. Invest. 29:7 (2006), 665–674.
247. [247] Antinozzi, C., Corinaldesi, C., Giordano, C., Pisano, A., Cerbelli, B., Migliaccio, S., Di Luigi, L., Stefanantoni, K., Vannelli, G.B., Minisola, S., Valesini, G., Riccieri, V., Lenzi, A., Crescioli, C., Potential role for the VDR agonist elocalcitol in metabolic control: evidences in human skeletal muscle cells. JSBMB, 2016, 10.1016/j.jsbmb.2016.12.010.
248. [248] 2-ALKYLIDENE-18, 19-DINOR-VITAMIND COMPOUNDS. United States Patent Application Publication Pub. No.: US 2010/0179344 A1 (2010).
249. [249] Cantorna, M.T., Hayes, C.E., DeLuca, H.F., 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 93:15 (1996), 7861–7864.
250. [250] Larsson, P., Mattsson, L., Klareskog, L., Johnsson, C., A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia. Clin. Exp. Immunol. 114:November (2) (1998), 277–283.
251. [251] Crescioli, C., Minisola, S., Vitamin D, autoimmunity and gender. Curr. Med. Chem.(December 19), 2016, 10.2174/0929867323666161220105821.
252. [252] Allan, G.M., Vitamin D: a narrative review examining the evidence for ten beliefs. J. Gen. Intern. Med. 31:July 7 (2016), 780–791.
253. [253] Plum, L.A., DeLuca, H.F., Vitamin D, disease and therapeutic opportunities. Nat. Rev. Drug Discov. 9:12 (2010), 941–955 (Rev).
254. [254] Endres, D.B., Investigation of hypercalcemia. Clin. Biochem. 45:12 (2012), 954–963.
255. [255] Glerup, H., Mikkelsen, K., Poulsen, L., Hass, E., Overbeck, S., Thomsen, J., Charles, P., Eriksen, E.F., Commonly recommended daily intake of vitamin D is not sufficient if sunlight exposure is limited. J. Intern. Med. 247 (2000), 260–268.
256. [256] Boonen, S., Bischoff-Ferrari, H.A., Cooper, C., Lips, P., Ljunggren, O., Meunier, P.J., Reginster, J.Y., Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif. Tissue Int. 78:5 (2006), 257–270.
257. [257] Larsen, E.R., Mosekilde, L., Foldspang, A., Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J. Bone Miner. Res. 19:3 (2004), 370–378.
258. [258] Bouillon, R., Vitamin D: from photosynthesis, metabolism, and action to clinical applications. DeGroot, L.J., Jameson, J.L., (eds.) Endocrinology, 2001, W.B. Saunders, Philadelphia, 1009–1028.
259. [259] Holick, M.F., Garabedian, M., Vitamin D: photobiology metabolism, mechanism of action, and clinical applications. In Primer on the metabolic bone diseases and disorders of mineral metabolism. 6 edition. Edited by: favus MJ. Washington, DC. Am. Soc. Bone Miner. Res., 2006, 129–137.
260. [260] Holick, M.F., Resurrection of vitamin D deficiency and rickets. J. Clin. Invest. 116:8 (2006), 2062–2072.
261. [261] Vieth, R., Why the optimal requirement for vitamin D3 is probably much higher than what is officially recommended for adults. J. Steroid Biochem. Mol. Biol. 89–90:1–5 (2004), 575–579 (Proceedings of the 12th Worksho on Vitamin D).